The present invention relates to methods for treating cell proliferation disorders comprising (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated, (2) administering at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder, and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes.

A radiation device directs a beam of radiation onto a target. The beam can be adjusted using, for example, a control for setting beam shape and a control for setting beam intensity. The target is supported on a surface that can be adjusted using, for example, a control for setting surface position and a control for setting a speed for moving the surface. Controls are selected to adjust the beam and the surface cooperatively in order to compensate for movement of the target.

The disclosure relates to a device and a method for the treatment of diseases of the skin, glands, mucousae, connective tissue, nerves and/or horny tissue. The device is adapted for the treatment of diseases of the skin, glands, mucousae, connective tissue, nerves and/or horny tissue and has at least one applicator, which applicator is arranged outside the device housing; at least one radio wave module, which radio wave module is adapted to generate an adjustable electromagnetic radiation with a variable frequency or with at least one constant frequency with an adjustable variable or at least one adjustable constant intensity.

Disclosed is a high power VCSEL laser treatment device with a skin cooling function, comprising VCSEL array (4) packaged on a laser heat sink (2), an optical transmission device (8) arranged in front of light-exiting faces of the VCSEL array (4) and a high-heat-conductivity optical window sheet (6) adhered to the light-exiting port end of the optical transmission device (8). An integrally molded cooling conduction metal piece (1) is arranged on the outer sides of the laser heat sink (2), the optical transmission device (8) and the high-heat-conductivity optical window sheet (6). In addition, one or more semiconductor chilling plates (7) are arranged between the cooling conduction metal piece (1) and the laser heat sink (2). In the above-mentioned high power VCSEL semiconductor laser treatment device, the semiconductor chilling plates (7) and the VCSEL array (4) share the heat sink, so that the inner structure is simplified.

A quantum wave therapy apparatus includes a quantum wave generator and a quantum wave irradiator. The quantum wave irradiator includes an oscillation plate, and a resin panel that is formed by kneading semiconductor powder, which reflects quantum waves, into resin. The quantum wave generator includes an AC adaptor, and a coil that is connected in series to the negative electrode side of an output smoothing capacitor in the AC adaptor, and that constitutes a serial resonance circuit. An electromotive voltage induced in the serial resonance circuit by extraneous electromagnetic waves is superimposed on a negative potential output from the AC adaptor, and a resulting voltage is applied to the oscillation plate, whereby quantum waves are generated. The quantum waves are applied to a diseased portion. The quantum waves reflected from surroundings are reflected again by the semiconductor powder in the resin panel and are applied to the diseased portion repeatedly.

A quantum wave therapy apparatus includes a quantum wave generator and a quantum wave irradiator. The quantum wave irradiator includes an oscillation plate, and a resin panel that is formed by kneading semiconductor powder, which reflects quantum waves, into resin. The quantum wave generator includes an AC adaptor, and a coil that is connected in series to the negative electrode side of an output smoothing capacitor in the AC adaptor, and that constitutes a serial resonance circuit. An electromotive voltage induced in the serial resonance circuit by extraneous electromagnetic waves is superimposed on a negative potential output from the AC adaptor, and a resulting voltage is applied to the oscillation plate, whereby quantum waves are generated. The quantum waves are applied to a diseased portion. The quantum waves reflected from surroundings are reflected again by the semiconductor powder in the resin panel and are applied to the diseased portion repeatedly.

A modular applicator for enabling a brachytherapy treatment comprising a central element and one or more of peripheral elements, wherein the central element is adapted with a fixation mechanism having a core for affixing the said peripheral elements thereto, wherein the fixation mechanism prevents a rotational displacement of the peripheral elements attached to the core of the fixation element with respect to the central element.

Methods for treating polycystic kidney disease with therapeutic renal neuromodulation and associated systems and methods are disclosed herein. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a renal artery of a kidney of a patient. One or more measurable physiological parameter corresponding to the polycystic kidney disease can thereby be reduced. Moreover, central sympathetic drive in the patient can be reduced in a manner that treats the patient for the polycystic kidney disease. Renal sympathetic nerve activity can be modulated along the afferent and/or efferent pathway. The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a neuromodulation assembly, e.g., a neuromodulation assembly configured to cryotherapeutically cool the renal nerve or to deliver an energy field to the renal nerve.

Methods for treating polycystic kidney disease with therapeutic renal neuromodulation and associated systems and methods are disclosed herein. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a renal artery of a kidney of a patient. One or more measurable physiological parameter corresponding to the polycystic kidney disease can thereby be reduced. Moreover, central sympathetic drive in the patient can be reduced in a manner that treats the patient for the polycystic kidney disease. Renal sympathetic nerve activity can be modulated along the afferent and/or efferent pathway. The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a neuromodulation assembly, e.g., a neuromodulation assembly configured to cryotherapeutically cool the renal nerve or to deliver an energy field to the renal nerve.

Radiofrequency (RF) skin treatment devices and methods are provided herein. RF energy is delivered via electrodes in a phase-controlled manner which heats skin volumes below the surface more than the skin surface itself. At least one electrode at least partially encloses at least one other electrode. The combination of controlling the phases of the RF energy delivered to different electrodes and the enclosing configuration of the electrodes allows concentrating the delivered energy in specific regions below the skin surface at a particularly high efficiency. Configurations of the enclosing and the enclosed electrodes, their forms and combinations with other electrodes and the phase polarities applied to the electrodes are also provided.